
Opinion|Videos|June 21, 2024
Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.
Advertisement
- Provide a brief overview of the treatment landscape, and where topical therapies and systemic therapies fit into this landscape. What are the current unmet needs from your perspective?
- Please incorporate a discussion of the following topical therapies:
- Corticosteroids
- Crisaborole –
AD-301/AD-302 ,CrisADe CARE 1 - Ruxolitinib – TRuE-AD1/TRuE-AD2 –
original publication ,long-term follow up
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5